China Patent Strategy https://validator.w3.org/feed/docs/rss2.html Why Do Examiners Fail to Recognize the Importance of my “Parameter Features”? IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 3: The 15-Day Mailing Period is Mostly Going Away Patent Eligibility for Software in China Everything you need to know about Patent Term Adjustment (PTA) in China How to Protect a Crystal Form (Polymorph) Patent in China Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical <strong>CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants</strong> Thin Disclosure but “Bulletproof” Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data How a Secondhand Ground Brush Wiped Away a Chinese Patent When Standards Evolve: How China Judges Inventiveness in Next-Gen Tech Patents Inventive Step for an Enantiomer over a Racemate: “L-ornidazole” Patent Invalidation Case US vs CN: Foreign Filing License Requirements Foreign companies transferring IP out of China: things to know New Policies to Promote Importation of Innovative Drugs Is it Sufficient to Claim an Antibody only by Describing its Antigen? Can Post Filing Data Overcome Inventive Step in China? No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements Markush claims in China – what can be arbitrarily deleted during invalidation? Finally a unified “Court of Appeal” for technology IP in China Major and Exciting Changes to China’s Patent Law [Fourth Amendment to China’s Patent Law] China Divisional Practice AI, Big Data, and Blockchain – CNIPA seeks public comment on draft patent examination guidelines Hong Kong Launches New Original Grant Patent System Diagnostic Claims in China China Provides Specific Directions to Strengthen Patent / Technology Protection from 2020 to 2021 First Ever Successful Invalidation Challenge Due to Unauthorized Foreign Filing Stay Ahead: Getting a Chinese Patent in Three Months? From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data Updates on Hong Kong Patents Examination Guidelines in 2024 Miss the 12-month Filing Deadline? China Finally Allows Patent Applicants to Restore, Add, or Correct a Priority Claim New Remedy in China for Fixing “Errors” in a Patent Application: Incorporation by Reference About Our Contributors Twice the Trouble: Unraveling a Single Case of Dual Patent and Trademark Infringement Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 1: Delayed Examination A More Detailed Overview of China’s Patent Term Extension (PTE) System The Secret Prior Art Trap: A Case Study on Conflicting Applications in China AI is magical but NOT magic! Be specific in your AI patents! NMPA’s Releases Draft Measures for Data Protection (Data Exclusivity) RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges New Fee Standards Released for Chinese Patent Applications Obviousness: can features from different categories of products be combined to invalidate a design patent? Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case First ever Invalidation decision on an RNAi Invention patent in China Announcement: Implementation Regulations (Rules) of the Chinese Patent Law have been Approved